Published in J Med Chem on May 01, 2014
Crystal Structure of the Human Cannabinoid Receptor CB1. Cell (2016) 1.50
Novel Electrophilic and Photoaffinity Covalent Probes for Mapping the Cannabinoid 1 Receptor Allosteric Site(s). J Med Chem (2015) 0.87
Medicinal chemistry of cannabinoids. Clin Pharmacol Ther (2015) 0.86
Diarylureas as allosteric modulators of the cannabinoid CB1 receptor: structure-activity relationship studies on 1-(4-chlorophenyl)-3-{3-[6-(pyrrolidin-1-yl)pyridin-2-yl]phenyl}urea (PSNCBAM-1). J Med Chem (2014) 0.79
AM841, a covalent cannabinoid ligand, powerfully slows gastrointestinal motility in normal and stressed mice in a peripherally restricted manner. Br J Pharmacol (2015) 0.78
Keys to Lipid Selection in Fatty Acid Amide Hydrolase Catalysis: Structural Flexibility, Gating Residues and Multiple Binding Pockets. PLoS Comput Biol (2015) 0.77
In vitro and non-invasive in vivo effects of the cannabinoid-1 receptor agonist AM841 on gastrointestinal motor function in the rat. Neurogastroenterol Motil (2015) 0.77
Structure-activity relationships of substituted 1H-indole-2-carboxamides as CB1 receptor allosteric modulators. Bioorg Med Chem (2015) 0.77
Crystal structures of agonist-bound human cannabinoid receptor CB1. Nature (2017) 0.75
A high efficacy cannabinergic ligand (AM4054) used as a discriminative stimulus: Generalization to other adamantyl analogs and Δ(9)-THC in rats. Pharmacol Biochem Behav (2016) 0.75
3'-functionalized adamantyl cannabinoid receptor probes. J Med Chem (2015) 0.75
Crystal structure of rhodopsin: A G protein-coupled receptor. Science (2000) 28.60
Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science (1992) 16.31
Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature (1990) 13.60
Molecular characterization of a peripheral receptor for cannabinoids. Nature (1993) 13.45
GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science (2007) 11.74
Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem Pharmacol (1995) 8.09
2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem Biophys Res Commun (1995) 6.55
Determination and characterization of a cannabinoid receptor in rat brain. Mol Pharmacol (1988) 5.54
Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet (2007) 5.49
Cannabinoid receptor localization in brain. Proc Natl Acad Sci U S A (1990) 5.48
Molecular signatures of G-protein-coupled receptors. Nature (2013) 5.19
Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science (2005) 5.12
Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science (1997) 3.16
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem (1999) 2.73
Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo. Proc Natl Acad Sci U S A (2009) 2.68
Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. Brain Res (2006) 2.62
Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science (2002) 2.50
CB2 cannabinoid receptor activation produces antinociception by stimulating peripheral release of endogenous opioids. Proc Natl Acad Sci U S A (2005) 2.36
Peripheral CB1 cannabinoid receptor blockade improves cardiometabolic risk in mouse models of obesity. J Clin Invest (2010) 2.32
HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor. Proc Natl Acad Sci U S A (1999) 2.32
Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS. Proc Natl Acad Sci U S A (2003) 2.29
Cyclohexylcarbamic acid 3'- or 4'-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modeling studies. J Med Chem (2004) 2.05
Brain cannabinoid CB₂ receptors modulate cocaine's actions in mice. Nat Neurosci (2011) 1.88
(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem (1994) 1.80
Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci U S A (2004) 1.66
Inhibition of inflammatory hyperalgesia by activation of peripheral CB2 cannabinoid receptors. Anesthesiology (2003) 1.60
Structure-activity relationships in cannabinoids. Pharmacol Rev (1986) 1.52
Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci U S A (1999) 1.51
CB2 cannabinoid receptor mediation of antinociception. Pain (2006) 1.47
AM630, a competitive cannabinoid receptor antagonist. Life Sci (1995) 1.46
The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology (2007) 1.44
The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) (2009) 1.42
Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience (2003) 1.42
Activation of the cannabinoid 2 receptor (CB2) protects against experimental colitis. Inflamm Bowel Dis (2009) 1.35
Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol (2004) 1.33
A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol (2010) 1.32
(-)-7'-Isothiocyanato-11-hydroxy-1',1'-dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol Pharmacol (2005) 1.24
Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. Chem Biol (2008) 1.22
Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav (2007) 1.22
Discovery of PF-04457845: A Highly Potent, Orally Bioavailable, and Selective Urea FAAH Inhibitor. ACS Med Chem Lett (2011) 1.21
Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol (2007) 1.21
Selective activation of cannabinoid CB2 receptors suppresses hyperalgesia evoked by intradermal capsaicin. J Pharmacol Exp Ther (2003) 1.20
Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. J Med Chem (2007) 1.19
Covalent inhibitors of human monoacylglycerol lipase: ligand-assisted characterization of the catalytic site by mass spectrometry and mutational analysis. Chem Biol (2008) 1.18
Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem (1998) 1.16
A neutral CB1 receptor antagonist reduces weight gain in rat. Am J Physiol Regul Integr Comp Physiol (2007) 1.15
Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem Biophys Res Commun (1997) 1.14
AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis. Eur J Pharmacol (2006) 1.14
Quantitative method for the profiling of the endocannabinoid metabolome by LC-atmospheric pressure chemical ionization-MS. Anal Chem (2007) 1.13
Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem (1996) 1.12
Inhibition of pain responses by activation of CB(2) cannabinoid receptors. Chem Phys Lipids (2002) 1.12
Potentiation of anandamide hypotension by the transport inhibitor, AM404. Eur J Pharmacol (1997) 1.11
Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem (1998) 1.11
Selective activation of cannabinoid CB2 receptors suppresses neuropathic nociception induced by treatment with the chemotherapeutic agent paclitaxel in rats. J Pharmacol Exp Ther (2008) 1.10
The cannabinoid system and its pharmacological manipulation--a review, with emphasis upon the uptake and hydrolysis of anandamide. Fundam Clin Pharmacol (2006) 1.10
Adamantyl cannabinoids: a novel class of cannabinergic ligands. J Med Chem (2005) 1.09
High affinity electrophilic and photoactivatable covalent endocannabinoid probes for the CB1 receptor. J Med Chem (2005) 1.08
Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma. J Lipid Res (2010) 1.08
How lipophilic cannabinergic ligands reach their receptor sites. Prostaglandins Other Lipid Mediat (2005) 1.07
Full mass spectrometric characterization of human monoacylglycerol lipase generated by large-scale expression and single-step purification. J Proteome Res (2008) 1.06
Comprehensive profiling of the human circulating endocannabinoid metabolome: clinical sampling and sample storage parameters. Clin Chem Lab Med (2008) 1.06
The conformation, location, and dynamic properties of the endocannabinoid ligand anandamide in a membrane bilayer. J Biol Chem (2005) 1.05
Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties. Physiol Behav (2007) 1.04
Crystal structure of a soluble form of human monoglyceride lipase in complex with an inhibitor at 1.35 Å resolution. Protein Sci (2011) 1.03
Novel 1',1'-chain substituted hexahydrocannabinols: 9β-hydroxy-3-(1-hexyl-cyclobut-1-yl)-hexahydrocannabinol (AM2389) a highly potent cannabinoid receptor 1 (CB1) agonist. J Med Chem (2010) 1.03
Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387. Pharmacol Biochem Behav (2006) 1.01
Design and synthesis of the CB1 selective cannabinoid antagonist AM281: a potential human SPECT ligand. AAPS PharmSci (1999) 1.00
Dual modulation of endocannabinoid transport and fatty acid amide hydrolase protects against excitotoxicity. J Neurosci (2005) 1.00
Intrathecal cannabilactone CB(2)R agonist, AM1710, controls pathological pain and restores basal cytokine levels. Pain (2012) 0.99
C1'-cycloalkyl side chain pharmacophore in tetrahydrocannabinols. J Med Chem (2007) 0.99
Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats. Br J Pharmacol (2010) 0.99
Comprehensive proteomic mass spectrometric characterization of human cannabinoid CB2 receptor. J Proteome Res (2007) 0.98
Endocannabinoid enhancement protects against kainic acid-induced seizures and associated brain damage. J Pharmacol Exp Ther (2007) 0.97
Cannabinoids. 3. Synthetic approaches to 9-ketocannabinoids. Total synthesis of nabilone. J Org Chem (1977) 0.97
A novel electrophilic high affinity irreversible probe for the cannabinoid receptor. Life Sci (1995) 0.95
Potential anxiogenic effects of cannabinoid CB1 receptor antagonists/inverse agonists in rats: comparisons between AM4113, AM251, and the benzodiazepine inverse agonist FG-7142. Eur Neuropsychopharmacol (2009) 0.95
Endocannabinoid metabolomics: a novel liquid chromatography-mass spectrometry reagent for fatty acid analysis. AAPS J (2006) 0.95
Locomotor activity and occupancy of brain cannabinoid CB1 receptors by the antagonist/inverse agonist AM281. Synapse (2000) 0.94
Syntheses of 1 -tetrahydrocannabinol and related cannabinoids. J Am Chem Soc (1972) 0.94
(-)-11-Hydroxy-7'-isothiocyanato-1',1'-dimethylheptyl-delta 8-THC: a novel, high-affinity irreversible probe for the cannabinoid receptor in the brain. J Med Chem (1994) 0.93
Dual inhibition of endocannabinoid catabolic enzymes produces enhanced antiwithdrawal effects in morphine-dependent mice. Neuropsychopharmacology (2013) 0.93
Pharmacological characterization of AM1710, a putative cannabinoid CB2 agonist from the cannabilactone class: antinociception without central nervous system side-effects. Pharmacol Biochem Behav (2011) 0.93
The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior. Pharmacol Biochem Behav (2010) 0.92
The CB1 inverse agonist AM251, but not the CB1 antagonist AM4113, enhances retention of contextual fear conditioning in rats. Pharmacol Biochem Behav (2010) 0.92
Membrane phospholipid bilayer as a determinant of monoacylglycerol lipase kinetic profile and conformational repertoire. Protein Sci (2013) 0.92
5'-Azido-delta 8-THC: a novel photoaffinity label for the cannabinoid receptor. J Med Chem (1992) 0.91
Cannabinoid receptors and the regulation of bone mass. Br J Pharmacol (2007) 0.91
Amphipathic interactions of cannabinoids with membranes. A comparison between delta 8-THC and its O-methyl analog using differential scanning calorimetry, X-ray diffraction and solid state 2H-NMR. Biochim Biophys Acta (1992) 0.90
The neutral cannabinoid CB₁ receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat. Pharmacol Biochem Behav (2010) 0.90
Oral bioavailability of the novel cannabinoid CB1 antagonist AM6527: effects on food-reinforced behavior and comparisons with AM4113. Pharmacol Biochem Behav (2008) 0.90
Immunofluorescent spectral analysis reveals the intrathecal cannabinoid agonist, AM1241, produces spinal anti-inflammatory cytokine responses in neuropathic rats exhibiting relief from allodynia. Brain Behav (2012) 0.90
Study of the topography of cannabinoids in model membranes using X-ray diffraction. Biochim Biophys Acta (1990) 0.89
Blocking cannabinoid activation of FAK and ERK1/2 compromises synaptic integrity in hippocampus. Eur J Pharmacol (2005) 0.89
High-performance liquid chromatographic determination of anandamide amidase activity in rat brain microsomes. Anal Biochem (1996) 0.89
Discriminative stimulus functions in rats of AM1346, a high-affinity CB1R selective anandamide analog. Psychopharmacology (Berl) (2008) 0.88
Novel adamantyl cannabinoids as CB1 receptor probes. J Med Chem (2013) 0.88
Controlled-deactivation cannabinergic ligands. J Med Chem (2013) 0.88
Purification and mass spectroscopic analysis of human CB1 cannabinoid receptor functionally expressed using the baculovirus system. J Pept Res (2005) 0.88
Mass spectrometry-based proteomics of human cannabinoid receptor 2: covalent cysteine 6.47(257)-ligand interaction affording megagonist receptor activation. J Proteome Res (2011) 0.88